ICON (NASDAQ: ICLR) will participate in the Jefferies Global Healthcare Conference and the Annual Evercore Healthcare Conference. (Neutral)How Sentiment works Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by ICON plc
ICON Launches FIRECREST AI-Directed Video Engine, Changing the Economics of Site Communications
Home News ICLR ICON Launches FIRECREST AI-Directed Video Engine, Changing the Economics of Site Communications ICON (ICLR) has launched AI-directed video production capabilities within its FIRECREST platform for clinical trial site and patient communications. (Neutral)How Sentiment works Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale.
ICON Schedules Third Quarter 2026 Earnings Conference Call
ICON (NASDAQ: ICLR) will release its third-quarter 2026 financial results after the market closes on Tuesday, October 27, 2026. (Neutral)How Sentiment works Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial
Study Set-Up and Design This was a multi-center, double-blind, randomized, placebo-controlled, two-way crossover Phase IV clinical trial conducted in patients with insomnia disorder and comorbid nocturia (clinicaltrials.gov NCT05597020). A cross‑over design was selected to minimize inter‑participant variability and reduce the influence of covariates by allowing each participant to serve as their own control, while also requiring a smaller sample size than a parallel‑group design.
The Adoption and Use of Artificial Intelligence and Machine Learning in Clinical Development - Therapeutic Innovation & Regulatory Science
Abstract The use of artificial intelligence (AI) and machine learning (ML) in drug discovery has been well documented, but measures of levels of adoption, investments, and efficiencies gained from its use in clinical development have not yet been developed, captured or published. AI/ML use in clinical development is expected to increase, but its impact has not yet been systematically measured until now.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, April 8, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
NEW YORK, April 8, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. kAm$@ H92Ei x7 J@F AFC492D65 xr~} @C5:?2CJ D92C6D 5FC:?8 E96 r=2DD !6C:@5 J@F >2J 36 6?E:E=65 E@ 4@>A6?D2E:@?
ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
State AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington D.C.West VirginiaWisconsinWyomingPuerto RicoUS Virgin IslandsArmed Forces AmericasArmed...
ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
INVESTOR DEADLINE THIS WEEK: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, April 7, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and January 13, 2025, all dates inclusive (the "Class Period"), have until Friday, April 11, 2025 to seek appointment as lead plaintiff of the ICON class action lawsuit. Captioned Shing v.
ICON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against ICON plc - ICLR
, /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 11, 2025 to file lead plaintiff applications in securities class action lawsuits against ICON plc (the "Company") (NasdaqGS: ICLR), if they purchased the Company's shares between July 27, 2023 and January 13, 2025, inclusive (the "Class Period"). These actions are pending in the United States District Court for the Eastern District of New York.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
, March 24, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
NEW YORK, March 24, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
kAmkDA2? 4=2DDlQ=686?5$A2?r=2DDQmkDA2? 4=2DDlQI?\=@42E:@?Qm}t( *~#zk^DA2?mk^DA2?m[ kDA2? 4=2DDlQ=686?5$A2?r=2DDQmkDA2? 4=2DDlQI?\49C@?Qm|2C49 ac[ a_adk^DA2?mk^DA2?m ^!#}6HDH:C6^ \\ #@D6? {2H u:C>[ 2 8=@32= :?G6DE@C C:89ED =2H 7:C>[ C6>:?5D AFC492D6CD @7 @C5:?2CJ D92C6D @7 xr~} A=4 W}p$sp"i xr{#X 36EH66? kDA2? 4=2DDlQI?\49C@?QmyF=J af[ a_abk^DA2?m 2?5 kDA2? 4=2DDlQI?\49C@?Qm~4E@36C ab[ a_ack^DA2?m[ 3@E9 52E6D :?4=FD:G6 WE96 Qr=2DD !6C:@5QX[ @7 E96 :>A@CE2?E kDA2?
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. kAm$@ H92Ei x7 J@F AFC492D65 xr~} @C5:?2CJ D92C6D 5FC:?8 E96 r=2DD !6C:@5 J@F >2J 36 6?E:E=65 E@ 4@>A6?D2E:@?
ICON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ICON plc - ICLR
NEW YORK and NEW ORLEANS, March 14, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 11, 2025 to file lead plaintiff applications in a securities class action lawsuit against ICON plc (the "Company") (NasdaqGS: ICLR), if they purchased the Company's shares between July 27, 2023 and October 23, 2024, inclusive (the "Class Period").
BusinessWire - ICON Plc (ICLR) ICON plc to Present at Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025 at 8.00 am ET and at the Barclays 27th Annual Global Healthcare Conference on Thursday, March 13, 2025 at 8.30 am ET.
ICON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ICON plc - ICLR
, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 11, 2025 to file lead plaintiff applications in a securities class action lawsuit against ICON plc (the "Company") (NasdaqGS: ICLR), if they purchased the Company's shares between July 27, 2023 and October 23, 2024, inclusive (the "Class Period").
ICON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ICON plc - ICLR
, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 11, 2025 to file lead plaintiff applications in a securities class action lawsuit against ICON plc (the "Company") (NasdaqGS: ICLR), if they purchased the Company's shares between July 27, 2023 and October 23, 2024, inclusive (the "Class Period").
ICLR INVESTOR NOTICE: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, Feb. 15, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), have until April 11, 2025 to seek appointment as lead plaintiff of the ICON class action lawsuit. Captioned Shing v.
Oral cannabidiol did not impair learning and memory in healthy adults - Journal of Cannabis Research
Information regarding the demographics of study participants is provided in Table 2. Among the 35 study participants retained for the analyses, 19 were female (54%) and the majority were between the ages of 18–27 (71.4%). The age of participants ranged from 18 to 64, with only four participants over 60. Most completed some college (49/2%) and 18 (51/4%) of the subjects self-identified as Caucasian.
Better Medicines for Children: Lessons Learnt and Share Learnings at the EFGCP Annual Paediatric Conferences - Therapeutic Innovation & Regulatory Science
Abstract For many years, the European Forum for Good Clinical Practice (EFGCP) Children Medicines Working Party has organised a Paediatric conference annually. In the past, this event was organised jointly with the European Medicines Agency who was used to host it, along with the Drug Information Association (DIA).
BusinessWire - ICON Plc (ICLR) ICON Reports Third Quarter 2024 Results
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended September 30, 2024. CEO, Dr. Steve Cutler commented, “ICON’s results for the third quarter did not meet the expectations we had previously provided due to specific customer and division-level impacts.
P07 Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA): results on critical care patients from a multinational, multicentre, observational analysis
Ceftolozane/tazobactam (C/T) is indicated for the treatment of complicated intra-abdominal infections (cIAI),1 complicated urinary tract infections (cUTI), including pyelonephritis,2 and hospital-acquired bacterial and ventilator-associated bacterial pneumonia.3 Information on real-world use and outcomes of patients treated with C/T in critical care settings is important to help inform disease management and clinical practice.
Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event - Trials
In-person attendees at the event included 32 individuals from diverse expertise backgrounds representing key silos across the ecosystem with interest and/or experience in digital endpoints, including clinicians, statisticians, computer scientists, implementation scientists, ethicists, health economists and patient and public representatives. Their experiences with digital endpoints spanned several disease areas, including pulmonary hypertension, dementia, Parkinsons’, women’s health and diabetes.
BusinessWire - ICON Plc (ICLR) ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:15pm PST/8.15pm EST. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “”.
Effect of Anti-TNF Biologic Exposure During Pregnancy on Villitis of Unknown Etiology Diagnoses in Patients with Autoimmune Disease - Reproductive Sciences
Abstract Tumor necrosis factor-α (TNF-α) antagonists are highly effective in controlling autoimmune diseases. This has led to speculation that they might also be useful in treating inflammatory placental conditions, such as chronic villitis of unknown etiology (VUE). VUE affects 10–15% of term placentas and is associated with recurrent fetal growth restriction (FGR) and pregnancy loss.
Pertinence of glioma and single nucleotide polymorphism of TERT, CCDC26, CDKN2A/B and RTEL1 genes in glioma: a meta-analysis
1 Introduction Gliomas, which occupy more than 80% primary malignant tumors of central nervous system, are presumably caused by the aberrant growth of glial cells, mostly in the brain and spinal cord (1). Based on the cell type from which they originate, gliomas may be divided into several categories such astrocytomas, oligodendrogliomas, and ependymomas. The World Health Organization first used molecular pathology in the diagnostic classification of gliomas in 2016(2).
A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
Highlights • MRG-001 exhibits immunoregulatory and regenerative properties in animal models • The phase I trial confirms the favorable safety profile for multiple-dose regimens • Stem cells and immunoregulatory T cells are successfully mobilized by MRG-001 • MRG-001 down-regulates 31 pathways related to inflammation and allograft rejection Summary Preclinical studies demonstrate that pharmacological mobilization and recruitment of endogenous bone marrow stem cells and immunoregulatory cells...
BusinessWire - ICON Plc (ICLR) First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry organisations as a leading CRO of choice and a top-rated employer in the first half of 2023. For its excellent performance in clinical research, ICON was named a recipient of the 2023 CRO Leadership Awards in the following categories: Capabilities, Compatibility, Expertise, Quality and Reliability.
BusinessWire - ICON Plc (ICLR) ICON plc Schedules Second Quarter 2023 Earnings Conference Call
(NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2023 after the market closes on Wednesday, July 26, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 27, 2023 at 8:00am ET.
BusinessWire - ICON Plc (ICLR) ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform
, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced the latest release of its . The platform supports seamless integration of ICON patient, site and sponsor services with the delivery of harmonised data and can be customised for any study design, from traditional to fully decentralised, and for any therapeutic area.
BusinessWire - ICON Plc (ICLR) ICON plc Set to Join Russell 3000® Index
, (NASDAQ: ICLR), is set to join the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today, Monday, June 26. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28, ranking them by total market capitalization, including both the Russell 3000® and Russell Microcap® Indexes.
Risk factors for hepatic hydrothorax in patients with cirrhosis: a clinical retrospective study
Introduction Hepatic hydrothorax (HH) is an important complication of decompensated cirrhosis and portal hypertension. It is a pleural effusion, typically of more than 500 mL, in patients with liver cirrhosis that do not present with coexisting underlying cardiac or pulmonary diseases (1, 2). The occurrence of HH has been reported in 4–16% of patients with cirrhosis.
BusinessWire - ICON Plc (ICLR) ICON plc to Attend Upcoming Investor Conferences
, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6, 2023 at 2:40pm CT and Mr. Brendan Brennan, CFO of ICON plc, will attend the UBS Healthcare Services Conference on Wednesday, June 28, 2023.
BusinessWire - ICON Plc (ICLR) ICON releases its 2022 ICON Cares ESG Report
, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its . The company’s ICON Cares initiative incorporates its ESG, Diversity, Inclusion and Belonging and Corporate Social Responsibility initiatives under one program. The report provides an overview of ICON’s ESG activities in 2022 and the progress it has made in advancing its ESG priorities.
BusinessWire - ICON Plc (ICLR) ICON Reports First Quarter 2023 Results
(NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2023. CEO, Dr. Steve Cutler commented, “ICON’s first quarter results reflect continued demand for our broad portfolio of services despite the challenging macroeconomic environment.
A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis” - Advances in Therapy
Dear Editor, We would like to thank you for allowing us the opportunity to respond to the letter received from Marshall et al. and to address the queries raised with respect to our network meta-analysis (NMA) of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of chronic obstructive pulmonary disease (COPD) [1].
BusinessWire - ICON Plc (ICLR) ICON plc Schedules First Quarter 2023 Earnings Conference Call
(NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2023 after the market closes on Wednesday, April 26, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 27, 2023 at 8:00am ET.
BusinessWire - ICON Plc (ICLR) LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
ICLR ICON Plc LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology , a global leader in medical dermatology, and (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with ICON
Contact ICON, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack